Alivus Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/07/2026 ,inter alia, to consider and approve the Unaudited Financial ....

July 23, 2026 To, To, Dy. General Manager The Manager – Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Ref: Scrip Code: 543322 Ref: Scrip Name: ALIVUS Dear Sirs, Sub: Board Meeting We have to inform you that, pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Thursday, July 30, 2026, inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2026. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, the Company has intimated its ‘designated persons’ regarding the closure of the Trading Window from July 1, 2026 to August 1, 2026 (both days inclusive) for the purpose of approval of Unaudited Financial Results for quarter ended June 30, 2026. The above is for your information. Thanking you. Yours faithfully, For Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) Rudalf Corriea Company Secretary & Compliance Officer Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited ) Corporate Office: R egistered Office: Technopolis Knowledge Park, A wingO, ffice No. 401 to 407, P lot No 170-172, Chandramouli Industrial Estate 4th Floor, Mahakali Caves Road, Andheri ( E), Mumba–i 400093 M ohol Bazarpeth, Solapur 413 213, India T: +91 22 6829 7979 | CIN: L74900PN2011PLC139963 | E: complianceofficer@alivus.com | W: www.alivus.com